Scientists at Roche and Harvard University have discovered an entirely new class of antibiotic that can kill a highly drug-resistant ‘superbug’ with a mortality rate that can be upwards of 50% ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

Medicines that fight bacteria, called antibiotics, are the main treatment for Lyme disease. It’s important to get treatment as early as possible to make a full recovery and avoid complications.